

Subject index

A

17-AAG, 30 (91), 32 (98), 52 (164), 77 (247), 97 (319), 99 (325), 100 (331), 105 (348), 176 (580)
Acute myelogenous leukemia, 128 (428)
Adenovirus, 134 (447), 196 (650)
Adhesion, 58 (185), 121 (403), 170 (561)
AKt, 14 (33, 34)
Akt, 14 (32), 44 (136), 76 (246), 77 (249), 84 (275), 96 (315), 101 (333), 102 (337), 104 (345), 105 (349), 106 (352), 113 (375), 116 (388), 119 (398), 135 (451), 167 (549), 170 (560)
Alkylating agent, 168 (552), 192 (636)
Angiogenesis, 22 (62), 25 (70), 39 (121), 43 (134), 44 (136), 45 (139, 141), 47 (148), 48 (152), 49 (155), 51 (162), 52 (163), 53 (168), 55 (173, 175, 176), 56 (177, 178), 57 (180, 181), 59 (190), 60 (192, 193), 100 (331), 139 (458, 461), 142 (466), 180 (595), 184 (608), 197 (653)
Angiogenesis inhibitors, 15 (39), 44 (135, 137), 46 (144), 47 (146), 50 (159), 125 (416), 175 (577), 195 (647)
Animal models, 7 (11), 19 (52), 24 (67, 68), 51 (160), 52 (163), 79 (257), 81 (262), 117 (392)
Anthracycline derivatives, 144 (472)
Anti-angiogenesis, 43 (132), 47 (147), 48 (150, 151), 49 (153), 51 (160, 161), 52 (165), 58 (186), 59 (188, 189), 136 (456)
Antibodies, 25 (70), 61 (197), 80 (261), 87 (286), 89 (293), 93 (306), 94 (307, 309, 310), 95 (312), 142 (466)
Antibody-drug conjugates, 91 (299), 93 (305), 94 (308)
Antibody fusion protein, 59 (188)
Antiproliferative, 23 (66), 58 (186), 168 (551)
Antisense, 13 (29), 17 (45), 50 (157), 66 (216), 131 (439), 132 (440, 442, 443), 134 (448, 449), 135 (453), 136 (457), 141 (465)
Apoptosis, 7 (12), 13 (29, 30), 17 (43), 19 (50), 21 (56), 23 (66), 25 (73), 27 (78), 30 (91), 32 (97), 39 (121), 41 (128), 42 (131), 60 (194), 61 (198), 62 (200, 201, 202), 63 (203, 204, 205), 64 (206, 207), 65 (210, 211, 213), 67 (217, 218, 220), 68 (222, 223, 224), 69 (225, 226, 227), 70 (228, 231), 71 (234), 72 (237), 82 (268), 84 (275), 94 (310), 97 (319), 99 (326), 103 (341), 107 (353), 111 (370), 112 (374), 126 (422), 127 (424), 139 (462), 141 (464), 156 (511), 170 (559, 560), 171 (563), 172 (567), 174 (574), 185 (612), 188 (623), 191 (634), 194 (643), 195 (646), 199 (659)
ATM, 125 (417), 145 (475)

B

Bcl-2, 63 (205), 66 (216), 107 (353), 132 (441), 133 (445), 141 (464, 465), 194 (643)

Bcr/Abl, 190 (628)

Bioinformatics, 34 (105), 197 (654)

Biomarker, 85 (278), 92 (302), 106 (351), 120 (402), 129 (432, 433), 177 (583)

Bioreductive, 57 (180), 150 (493), 151 (495, 497), 152 (498, 499, 500), 175 (577)

Brain tumour, 109 (363), 159 (521), 184 (609)

BRCA 1, 65 (211), 84 (274)

Breast cancer, 25 (70), 29 (85), 62 (201), 66 (215), 99 (325), 102 (337), 107 (356), 108 (357), 110 (365), 125 (418), 129 (433), 133 (446), 142 (467, 468), 155 (508), 174 (572), 178 (588, 589), 180 (594), 189 (625), 198 (657)

C

c-KIT, 25 (71), 85 (277), 106 (350)

c-myc, 171 (564)

Caspase, 62 (199), 70 (229), 71 (235), 136 (455)

CDK inhibitors, 26 (74), 38 (117), 124 (415), 126 (422), 127 (423), 129 (432)

Cell cycle, 23 (66), 30 (90), 69 (226), 125 (416), 126 (421), 127 (423, 424)

Chalcones, 38 (116)

Checkpoint, 20 (53), 67 (218), 125 (417)

Chemosensitivity, 148 (487)

Chemotherapy, 25 (71), 33 (99), 57 (182), 69 (227), 116 (389), 149 (489), 175 (576), 182 (602), 186 (615, 616), 189 (625), 199 (660)

Chromatin, 78 (250)

Colon cancer, 23 (65), 68 (222), 71 (232), 91 (297), 116 (389), 126 (421), 149 (488), 174 (572)

Colorectal cancer, 24 (68), 43 (133), 85 (279), 92 (300), 102 (336, 338), 133 (444), 134 (450), 145 (476), 149 (489), 179 (590), 188 (621)

Combination chemotherapy, 8 (14), 30 (92), 126 (420), 129 (430, 431), 133 (444), 149 (490), 171 (562)

Combination therapy, 18 (47), 71 (232), 163 (536), 181 (598), 192 (637)

COX-2, 19 (51)

Cytokines, 57 (181), 58 (184), 81 (263), 82 (267, 268), 84 (275), 101 (335), 119 (397), 188 (620)

Cytotoxicity, 41 (127)

D

Dendritic cells, 10 (24), 80 (258), 82 (266)

DNA, 157 (515), 165 (542, 543), 166 (544, 547), 168 (553), 169 (554), 170 (559)

DNA damage, 16 (40), 20 (53, 54), 60 (194), 63 (203), 152 (500)

DNA damage repair, 145 (474), 147 (482)
DNA methylation, 78 (250)
DNA repair, 145 (477), 146 (478, 479, 480, 481), 147 (483)
Drug delivery, 7 (10), 12 (26), 36 (111, 112), 37 (113),
 39 (120, 121), 40 (123), 41 (126), 46 (143), 70 (228),
 150 (492), 152 (499), 181 (600), 182 (603), 183 (604,
 605), 184 (607, 609), 185 (611), 186 (614)
Drug development strategy, 3 (1)
Drug discovery, 34 (104), 35 (106), 46 (144), 97 (318),
 172 (565)
Drug resistance, 27 (80), 99 (325), 108 (358), 127 (425),
 143 (469), 144 (471), 147 (484), 159 (521), 160 (524),
 161 (528), 162 (532), 163 (537), 164 (538), 170 (559),
 184 (610), 187 (618, 619), 188 (621, 622), 189 (624),
 190 (629), 191 (631, 632), 192 (638), 193 (639, 640),
 198 (658)
Drug resistance and modifiers, 173 (570), 190 (630)
Drug screening, 36 (110), 115 (383)
Drug targeting, 169 (555)

E

Efficacy, 71 (232), 144 (473), 162 (533), 173 (569)
EGFR, 178 (587)
EGFR-TK inhibitors, 86 (281), 96 (316), 102 (336), 120 (400)
Endothelial cells, 49 (153), 53 (168), 56 (177), 57 (183)
Epidermal growth factor receptor, 23 (64), 46 (145), 70 (229),
 85 (278), 86 (282), 87 (284, 285), 91 (298), 95 (313),
 96 (314), 102 (338), 105 (349), 108 (358), 110 (366,
 367), 111 (370), 112 (372), 116 (387), 117 (391),
 118 (393), 119 (399), 122 (407), 123 (410, 412),
 124 (414), 179 (590), 192 (638), 193 (642)
ErbB inhibitors, 16 (41), 92 (302)
Estrogen receptor, 84 (274)

F

Farnesyl transferase inhibitor, 107 (354), 113 (376)
FLT3, 94 (308)

G

G-quadruplex, 166 (545), 169 (557)
Gastro-intestinal cancers, 167 (549)
Gene expression, 15 (36, 37, 38), 23 (63), 30 (89), 31 (95),
 34 (103), 55 (174), 92 (302), 115 (384), 148 (487),
 165 (541), 166 (546), 197 (654)
Gene therapy, 57 (183), 131 (438), 134 (447), 135 (452, 454),
 136 (455)
Glioblastoma, 14 (31), 22 (61), 55 (174), 89 (292), 197 (654)
Glioma, 86 (282), 87 (283), 98 (324), 114 (379), 131 (439),
 173 (569), 193 (642)
Growth factor inhibitors, 45 (142), 59 (187)

H

HDAC inhibitor, 35 (108), 40 (125), 78 (252), 169 (556)
Head and neck cancer, 23 (64), 59 (187), 79 (254), 122 (408),
 150 (491), 196 (649)
Heat shock proteins, 10 (23), 79 (256)
Hepatocellular carcinoma, 16 (42), 143 (470), 189 (626)
HER-2/neu, 105 (348), 110 (367)
High throughput screening, 3 (4), 33 (102), 34 (103, 104,
 105), 35 (107, 109)
Histone deacetylase, 19 (50), 21 (58), 42 (129)
Histone deacetylase inhibitors, 21 (59), 28 (82, 83), 60 (193),
 78 (251, 253), 103 (339)

Hsp90, 21 (56), 22 (60), 28 (84), 31 (94), 32 (98), 52 (164),
 75 (240), 78 (252), 97 (319), 100 (331), 105 (347, 348)
Hypoxia, 21 (57), 32 (96), 55 (175), 57 (180), 59 (187, 190),
 75 (242, 243), 76 (244, 245), 83 (270), 99 (327),
 118 (395), 150 (491), 151 (495, 496), 152 (498),
 158 (517), 190 (627), 195 (647)

I

IGFBP2, 96 (315)
Imaging, 24 (67), 36 (112), 55 (173), 75 (242), 88 (288),
 90 (295), 98 (324), 101 (333), 111 (369, 370), 116 (386),
 133 (446), 150 (491), 172 (568)
Immunotherapy, 10 (24), 33 (101), 79 (255), 80 (258, 259,
 260), 81 (265), 89 (290), 120 (401)
Insulin-like growth factor, 87 (286), 108 (357), 116 (388)
Integrin receptor, 41 (127)
Invasion, 53 (168), 70 (230), 109 (361), 110 (364, 365),
 121 (405, 406), 184 (608)
Ionizing radiation, 198 (655)

J

JAK3, 104 (344)
JANEX-1, 104 (344)

K

Kinase inhibitors, 8 (16), 20 (53), 25 (73), 33 (102), 35 (106,
 109), 38 (118), 43 (134), 45 (139, 141), 47 (148),
 49 (154, 155), 50 (158), 54 (172), 55 (176), 97 (318),
 100 (329, 330), 103 (340, 342), 105 (346), 109 (361),
 110 (364), 111 (368), 118 (394), 121 (405, 406),
 125 (416), 193 (641)

L

Leukemia, 15 (37), 33 (100), 61 (195), 64 (206), 127 (426),
 174 (574), 177 (585)
Liposomes, 197 (652)
Liver cancer, 120 (400)
Lung cancer, 21 (56), 29 (87), 85 (277), 107 (355), 112 (372,
 373), 117 (391), 120 (402), 132 (442), 135 (454),
 145 (474), 148 (485), 177 (583), 184 (610), 194 (645)
Lymphoma, 71 (233)

M

MAPK, 17 (43), 107 (353), 108 (358)
Mass spectrometry, 3 (5), 36 (111), 85 (278)
Matrix metalloproteinases, 17 (44), 45 (140), 121 (403)
MDM2, 38 (116)
Melanoma, 25 (72), 33 (99), 35 (107), 47 (149), 54 (171),
 81 (264, 265), 88 (289), 133 (445), 149 (488)
Meta-iodobenzylguanidine, 37 (115)
Metastasis, 26 (75), 46 (143, 145), 48 (152), 52 (163),
 53 (168), 60 (191), 109 (361), 110 (364), 121 (405, 406),
 136 (456), 142 (467, 468), 190 (627)
Microarray, 15 (38), 66 (215), 128 (427), 160 (524), 161 (529),
 165 (541), 178 (589), 189 (624, 625)
Mitochondria, 63 (205)
Molecular targets, 18 (48), 67 (220)
Monoclonal antibodies, 13 (30), 51 (162), 52 (166), 63 (204),
 86 (282), 89 (292), 90 (294, 296), 91 (297), 92 (301),
 95 (311, 313), 113 (378)
mTOR, 8 (16), 14 (35), 16 (41), 122 (409), 123 (411), 172 (566)
Multiple myeloma, 75 (241), 91 (299), 187 (618)

N

Neuroblastoma, 37 (115), 57 (181), 106 (350), 155 (509)
Non-small cell lung cancer, 27 (77), 31 (94), 50 (159),
 51 (161), 79 (255), 124 (414), 128 (429), 132 (441),
 134 (450), 149 (490), 179 (592), 186 (615)
None, 3 (2), 7 (8, 9), 9 (18, 19, 20), 10 (21, 22), 11 (25),
 178 (586)

O

Octreotate, 37 (115)
Oligonucleotides, 17 (45), 38 (119), 132 (440, 442)
Oral administration, 167 (548)
Ovarian cancer, 23 (66), 66 (214), 92 (301), 118 (393),
 166 (546), 176 (582)

P

p53, 16 (40), 25 (72), 38 (116), 39 (122), 48 (150), 60 (194),
 62 (200), 71 (235), 72 (236), 167 (549), 179 (591),
 191 (634)
Pancreatic cancer, 30 (90), 41 (126), 134 (449), 148 (485)
PDK-1, 77 (249)
Peptide-conjugate, 41 (127)
Peptides, 26 (75), 33 (100), 58 (185), 79 (256), 80 (261),
 88 (289)
peptidomimetics, 40 (124)
Pharmacodynamics, 21 (58), 42 (131), 77 (248), 82 (267),
 101 (334), 103 (342), 105 (346), 122 (409), 123 (411),
 135 (453), 180 (593), 187 (617), 192 (635)
Pharmacogenomics, 153 (501)
Pharmacokinetics, 13 (29), 29 (86), 48 (151), 54 (172),
 58 (184), 59 (189), 61 (197), 82 (267), 89 (290), 93 (304),
 101 (334), 108 (359), 109 (362), 110 (366), 122 (409),
 123 (412), 129 (430, 431), 153 (501), 154 (504, 505),
 156 (510), 157 (514), 159 (520), 161 (529), 164 (539),
 167 (548, 550), 173 (571), 181 (599), 191 (633),
 192 (635)
Pharmacology, 183 (606)
Phase I, 13 (29, 30), 20 (55), 30 (92), 33 (99), 43 (132),
 44 (135, 137), 47 (147), 50 (156, 157), 52 (166),
 54 (170), 61 (197), 64 (208, 209), 67 (218), 70 (228),
 80 (258), 84 (276), 86 (280, 281), 88 (287), 101 (334),
 108 (359), 114 (381), 116 (387), 117 (390), 123 (411),
 412), 129 (430, 431), 132 (443), 148 (486), 151 (494),
 153 (501, 503), 154 (504, 506), 156 (510), 161 (529),
 163 (534, 535, 536), 164 (540), 167 (548, 550),
 181 (599), 183 (606)
Phase II, 16 (42), 43 (133), 45 (140), 79 (255), 80 (260),
 83 (271), 111 (369), 113 (377), 114 (382), 118 (393),
 122 (408), 126 (422), 155 (508), 174 (573), 177 (584)
PI3-Kinase, 8 (16), 14 (32), 31 (94), 53 (167), 77 (248),
 97 (320), 112 (374), 114 (379), 124 (414A), 145 (475),
 195 (646)
PK/PD, 20 (55), 36 (112), 37 (113), 53 (169), 89 (292),
 117 (390), 123 (413)
Platelet, 104 (344)
Platelet-derived growth factor receptor, 47 (148), 100 (328),
 109 (363)
Prodrugs, 57 (183), 150 (493), 151 (494, 496, 497), 175 (576),
 176 (579, 580), 183 (604)
Prognostic factor, 61 (196), 65 (212), 66 (214), 125 (418),
 419), 179 (591, 592)
Prostate cancer, 18 (48), 26 (76), 27 (78), 31 (93), 46 (143),
 55 (173), 80 (260), 83 (272), 89 (291, 293), 94 (309),
 108 (360), 114 (380), 115 (385), 132 (440), 134 (448),
 156 (511), 170 (558), 175 (575), 176 (581), 199 (661)
Proteasome inhibitors, 17 (43), 62 (202), 63 (203), 65 (213),
 75 (239, 241), 171 (563)
Proteomics, 3 (3, 5), 4 (6, 7), 37 (114), 55 (175)
Proteosomes, 75 (238)
PTEN, 96 (315)

R

Radiation, 8 (15), 29 (88), 42 (129), 45 (142), 56 (179),
 70 (231), 112 (371), 161 (530), 163 (537), 195 (646),
 196 (649, 651), 197 (653)
Radioimmunotherapy, 88 (288), 90 (295), 93 (303)
Radio sensitization, 104 (345), 194 (643, 644, 645), 197 (652),
 198 (656)
Radiotherapy, 14 (31), 32 (96), 49 (154), 89 (291, 293),
 90 (296), 94 (309), 135 (451)
Reactive oxygen species, 171 (563)
Renal cell carcinoma, 71 (235), 83 (271), 84 (276), 104 (343),
 111 (369), 136 (457), 188 (623)

S

Sarcoma, 15 (36), 45 (140), 100 (328), 113 (377), 114 (382),
 146 (479)
Signal transduction, 17 (44), 22 (61), 24 (69), 68 (221),
 84 (273), 96 (317), 98 (322), 101 (332), 102 (338),
 119 (396), 121 (404), 181 (597)
signal transduction inhibitor, 40 (124)
Skp2, 128 (428)
Solid tumours, 43 (132), 52 (166), 64 (209), 88 (287),
 160 (526), 164 (540)
Src family kinases, 190 (628)
Stat3, 30 (90), 38 (119), 40 (124), 113 (375)
Structure activity relationships, 41 (128), 42 (130), 155 (507)
Structure-based design, 38 (117)

T

Targeted therapy, 8 (14), 27 (79), 31 (93), 83 (269), 86 (280),
 95 (313), 98 (323), 115 (385)
Taxane analogs, 159 (522), 160 (524), 161 (528), 173 (571)
Taxol, 182 (601)
Telomerase, 130 (434, 435), 131 (437), 188 (622)
Telomeres, 61 (198), 130 (436), 166 (545), 188 (622)
Tetraplex DNA, 130 (435)
Thymidylate synthase, 181 (599)
Topoisomerase I, 153 (502, 503), 154 (506), 155 (507),
 156 (512, 513)
Topoisomerase II, 145 (477), 157 (515, 516), 158 (518)
TRAIL, 13 (30), 30 (91), 61 (197), 62 (199, 202), 63 (204),
 64 (208), 67 (219), 69 (225), 94 (310), 139 (463),
 192 (637)
TRAIL/APO-2L, 28 (81), 139 (462)
Tubulin, 53 (169), 103 (339), 158 (519), 159 (523), 160 (525),
 161 (527), 162 (531, 532), 163 (534, 535)
Tumour angiogenesis, 50 (158)
Tumour biomarkers, 12 (27), 19 (49)
Tumour models, 21 (59), 28 (82), 111 (368)
Tumour necrosis factor, 53 (167), 196 (650)
Tyrosine kinase, 13 (28), 47 (146), 118 (394), 123 (413),
 180 (596)

V

Vaccine, 10 (23, 24), 79 (256), 80 (259, 260, 261), 81 (262, 263, 264), 82 (266)
Vascular targeting, 44 (138), 47 (149), 56 (179)
VEGF, 43 (132), 50 (157), 56 (178), 57 (182), 59 (190), 60 (191), 136 (456), 139 (458, 459, 461)
VEGF inhibitors, 139 (460)
VEGF receptor, 16 (41), 18 (46), 25 (70), 44 (137), 45 (139), 47 (148), 49 (154, 155), 50 (159), 51 (160, 161, 162), 52 (165), 54 (172), 110 (367), 114 (381, 382), 116 (387), 123 (412)

X

Xenografts, 8 (13), 17 (45), 25 (71), 57 (182), 134 (448), 158 (517), 164 (538), 168 (552), 175 (578), 185 (613), 195 (648)